Finance
Tech stocks lead Nasdaq, S&P 500 rebound: A break down
The Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) indexes are rebounding from downward pressures that hit tech stocks (XLK) at the beginning of August. Now, Big Tech names, particularly Nvidia (NVDA), are seeing major gains. Why are tech stocks seeing this rebound and is it time to buy back into the sector?
Yahoo Finance markets reporter Josh Schafer joins Morning Brief to break down tech’s reversal from last week’s sell-off and how the sector is leading the market rally on Friday morning.
For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.
This post was written by Nicholas Jacobino
![](https://newspub.live/wp-content/uploads/2022/03/np-logo.png)
Finance
Binance exec insists bitcoin can recover despite 20% drop | Future Focus
On this week’s episode of Yahoo Finance Future Focus, our host Brian McGleenon interviews Vishal Sacheendran, Binance’s Head of Regional Markets, to discuss the current state of the cryptocurrency market. Despite bitcoin being down over 20% from its all-time high of $73,000 reached in May, Sacheendran suggests that several potential bullish catalysts could drive a recovery. Sacheendran expresses confidence that the current downturn in bitcoin and the broader cryptocurrency market doesn’t signal a long-term negative trend. He points to several factors that could benefit the digital asset, including the anticipated start of a U.S. Federal Reserve rate-cutting cycle and the upcoming U.S. presidential election, where pro-crypto candidates like Donald Trump and Robert F. Kennedy Jr. are making waves. Sacheendran emphasises the increased synchronicity between traditional financial markets and the cryptocurrency market, noting the growing presence of institutional investors and the introduction of Bitcoin and Ethereum ETFs. He highlights that market sentiment is optimistic, with the CME FedWatch tool showing a significant likelihood of a rate cut in September, which could further support a rebound in the cryptocurrency market.
Finance
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
![Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer](https://mma.prnewswire.com/media/884786/Armata_Logo.jpg?p=facebook)
LOS ANGELES, Aug. 15, 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company“), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata’s Corporate Controller, Richard Rychlik, will retain the position of Controller.
“We are delighted to welcome David to the Armata team,” stated Dr. Deborah Birx, Chief Executive Officer of Armata. “David’s extensive experience and track record of serving in senior accounting and finance roles within both clinical and commercial stage life sciences companies will serve us well as we continue to advance our two distinct programs – AP-PA02 and AP-SA02 – and prepare to initiate pivotal studies next year. This is an exciting time at Armata, and the addition of David to our senior team helps ensure that we are best positioned to achieve long-term success as we work to introduce an exciting new class of anti-infectives to treat serious drug-resistant bacterial infections.”
Before joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., a multi-channel physician-dispensed skincare company, from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company’s acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House’s experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the “SEC“) reporting.
Mr. House’s career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes, a public accounting firm. There, he managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr. House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton. He obtained his California Certified Public Accountant license, which is currently inactive.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Forward Looking Statements
This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the SEC, including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
Finance
Dare County receives award for excellence in financial reporting – The Coastland Times
![Dare County receives award for excellence in financial reporting – The Coastland Times Dare County receives award for excellence in financial reporting – The Coastland Times](https://www.thecoastlandtimes.com/wp-content/uploads/sites/55/2024/08/finance-1-copy.png)
Dare County receives award for excellence in financial reporting
Published 12:30 pm Thursday, August 15, 2024
1 of 3
Dare County has announced that, for the 33rd consecutive year, the Dare County Finance Department has been awarded the prestigious Certificate of Achievement for Excellence in Financial Reporting by the Government Finance Officers Association. The honor was received in recognition of the Finance Department’s annual comprehensive financial report that was developed for the fiscal year that ended on Friday, June 30, 2023.
The award – which is the highest form of recognition in governmental accounting and financial reporting – was formally presented to Dare County finance director David Clawson and assistant finance director Sally DeFosse by Dare County Board of Commissioners Chairman Bob Woodard during the board’s meeting that was held Monday, August 5, 2024.
Established in 1945 by the Government Finance Officers Association, the Certificate of Achievement for Excellence in Financial Reporting program is designed to encourage state and local governments to go above and beyond the minimum requirements of accounting principles and to prepare a financial report that provides full disclosure and transparency to the members of the community that particular government serves.
According to the Government Finance Officers Association, the purpose of the program is not to assess the financial health or status of participating state and local governments, but rather to ensure that citizens have all of the information needed to perform such an assessment themselves.
In order for an annual comprehensive financial report to be eligible for this award, a wide array of detailed financial information must be compiled and then condensed into a single, comprehensive document that can easily be accessed and understood by all citizens within the community, regardless of how familiar or experienced they may be with navigating the intricacies of complex financial information.
“Creating a report that fills all of the criteria that this prestigious award requires is incredible,” said Woodard. “It’s time-consuming, it’s challenging, and it makes it a massive achievement for local governments to attain. So the fact that Dare County has received this Certificate of Achievement for Excellence in Financial Reporting consistently for 33 consecutive years speaks volumes about the exceptional talent that we have within our entire Finance Department – particularly Dave Clawson and Sally DeFosse. They’ve been instrumental in developing this annual report, which has been recognized with this prestigious award for decades.”
As he continued his presentation, Woodard highlighted the fact that Dare County has received the award every single year since Clawson starting serving in his role as Dare County finance director and offered a considerable amount of praise for his ongoing efforts over the years, as well as the incredibly talented team of dedicated staff members that comprise the Dare County Finance Department.
“Dave’s outstanding leadership, along with the remarkable team he has built within our Finance Department, deserves special recognition – and of course Sally is also a key player in our Finance Department’s success,” said Woodard. “Her many responsibilities include developing Dare County’s annual budget and producing the Annual Comprehensive Financial Report. She plays an integral role in the county receiving this honor, which, as I previously mentioned, is the highest form of recognition for government accounting and financial reporting.”
Woodard continued, “In addition to Dave and Sally, I’d be remiss if I didn’t also recognize the Dare County Finance Department as a whole because I know that this accomplishment is a team effort. So many dedicated employees in the Finance Department have made significant contributions in their work every day, ultimately resulting in the county receiving this award again in 2024.”
To view Dare County’s annual comprehensive financial report for the fiscal year that ended on June 30, 2023, go to: darenc.gov/home/showpublisheddocument/12975/638370221466630000.
READ ABOUT MORE NEWS HERE.
SUBSCRIBE TO THE COASTLAND TIMES TODAY!
-
News1 week ago
The ‘Blue Walz’: How a low-key Midwestern governor shot to the top to be Harris’ VP pick | CNN Politics
-
Culture1 week ago
If that was it for Simone Biles' Olympic career, let's all appreciate what we just saw
-
World1 week ago
The day after in Dhaka
-
Movie Reviews1 week ago
‘Confession’ Review: A Live-Action Manga Adaptation Crams Maximum Menace Into One Cabin
-
Ohio2 days ago
Ohio taxpayers sent families $966 million for private school tuition: Capitol Letter
-
World1 week ago
Ex-Catalan leader Puigdemont headed back to Spain despite fear of arrest
-
Politics1 week ago
Kamala Harris shuts down anti-Israel protesters during campaign speech in Michigan: 'I'm speaking'
-
News1 week ago
Americans wounded in rocket attack on Iraq base